Medinotec Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Medinotec Inc (MDNC) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Medinotec Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 10M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+25.4% annualized vs trailing 12 months).
- Scale: Medinotec Inc ranks #137 of 246 companies by market capitalization in the Medical Equipment & Supplies industry, holding 0.0% of industry market cap.
- Peer revenue share: Medinotec Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
MDNC Sales vs. its Competitors, Q2 2026
Medinotec Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
For context: the Medical Equipment & Supplies industry grew revenue 15.0% year over year, combined, vs -1.1% for Medinotec Inc. Medinotec Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Medinotec Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Medinotec Inc | Yes | No | No | No |
| Competitors combined (32) | ||||
| High-Confidence Competitors (7) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 87.50 % (7 of 8) | 0.00 % (0 of 8) | 0.00 % (0 of 8) | 25.00 % (2 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
MDNC Stock Performance relative to its Competitors
MDNC Stock Performance relative to High-Confidence Competitors
MDNC Stock Performance relative to Similar-Size Competitors
MDNC Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Axogen inc | 282.9% | Outperformed |
| 2 | Monogram technologies inc | 282.9% | Outperformed |
| 3 | Bioventus Inc | 282.9% | Outperformed |
| 4 | Tenon Medical Inc | 282.9% | Outperformed |
| 5 | Livanova Plc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Medinotec Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Medinotec Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Medinotec Inc | 58.78 | 10.21 |
| Intuitive Surgical Inc | 151,973.98 | 11,296.30 |
| Medtronic Plc | 122,251.56 | 37,542.00 |
| Stryker Corp | 116,722.54 | 25,837.00 |
| Boston Scientific Corporation | 66,919.05 | 20,997.00 |
| Edwards Lifesciences Corporation | 51,417.95 | 6,512.50 |
| SUBTOTAL | 574,738.91 | 132,304.59 |
Sign in to see all competitors of Medinotec Inc .
Sources: Medinotec Inc's official press releases and company reports; CSIMarket.com's market research; and the company reports and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Medinotec Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Medinotec Inc's Competitors Named by the Company
Competitive relationships identified from Medinotec Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Cadence | Company report | 85% |
| Johnson & Johnson | Company report | 85% |
| B. Braun | Company report | 85% |
| Cordis | Company report | 85% |
| Teleflex | Company report | 85% |
| Conmed | Company report | 85% |
| Medtronic | Company report | 85% |
| Boston Scientific | Company report | 85% |
| Endotec | Company report | 85% |
| Cook Medical | Company report | 85% |
| Merit Medical | Company report | 85% |
| Fuse Medical Inc | Company report | 85% |
| Zimvie Inc | Company report | 85% |
| Vicarious Surgical Inc | Company report | 85% |
| Orthopediatrics Corp | Company report | 85% |
| Edwards Lifesciences Corporation | Company report | 85% |
| Zimmer Biomet Holdings Inc | Company report | 85% |
| Adagio Medical Holdings inc | Company report | 85% |
| Stryker Corp | Company report | 85% |
| Asensus Surgical Inc | Company report | 85% |
| Procept Biorobotics Corporation | Company report | 85% |
| Globus Medical Inc | Company report | 85% |
| Encision Inc | Company report | 85% |
| Utah Medical Products Inc | Company report | 85% |
| Bioventus Inc | Company report | 85% |
| Surgalign Holdings Inc | Company report | 85% |
| Smith and Nephew Plc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Medinotec Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from Medinotec Inc reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.
Medinotec Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Medinotec Inc | Outside USA Distribution Agreement Sales 86.05 % |
| Medtronic Plc | CARDIOVASCULAR 38.34 % |
| Stryker Corp | MedSurg and Neurotechnology 55.02 % |
| Boston Scientific Corporation | Cardiovascular 67.31 % |
| Edwards Lifesciences Corporation | United States 57.64 % |
| Globus Medical Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Medinotec Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Medinotec Inc | 59 | - | - |
| Intuitive Surgical Inc | 151,974 | 663,668 | 185,530 |
| Medtronic Plc | 122,252 | 395,179 | 55,463 |
| Stryker Corp | 116,723 | 461,375 | 66,589 |
| Boston Scientific Corporation | 66,919 | 355,881 | 62,186 |
| Edwards Lifesciences Corporation | 51,418 | 407,031 | 62,725 |
| PEERS TOTAL | 574,680 | 405,263 | 50,415 |
Medinotec Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Intuitive Surgical Inc | Geographic Distribution, Foreign 30.41 % |
| Medtronic Plc | United States 49.83 % |
| Stryker Corp | United States 75.26 % |
| Boston Scientific Corporation | United States 63.11 % |
| Globus Medical Inc | United States 79.61 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Medinotec Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 220 companies in Medinotec Inc's industry classification, broader than the peer set above. Market cap in millions of $.Medinotec Inc ranks #137 of 220 companies by market capitalization in its industry, holding 0.01 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 606, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Intuitive Surgical Inc | 156,497 | 13.68 % |
| 2 | Medtronic Plc | 121,609 | 10.63 % |
| 3 | Stryker Corp | 117,498 | 10.27 % |
| 4 | 3m Company | 89,555 | 7.83 % |
| 5 | Boston Scientific Corporation | 1,234 | 5.2% |
| 6 | Becton Dickinson And Company | 1,234 | 5.2% |
| 7 | Edwards Lifesciences Corporation | 1,234 | 5.2% |
| 8 | Resmed Inc | 1,234 | 5.2% |
| 9 | Alcon inc | 1,234 | 5.2% |
| 10 | Dexcom Inc | 1,234 | 5.2% |
| 137 | Medinotec Inc | 59 | 0.01 % |
Market cap and industry share for the rest of Medinotec Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-10-19.
Medinotec Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 132 | Envoy Medical Inc | 66 | -25.41 % |
| 133 | Lucid Diagnostics Inc | 64 | -71.77 % |
| 134 | Microbot Medical Inc | 64 | -64.90 % |
| 135 | Polypid Ltd | 63 | 45.88 % |
| 136 | Tela Bio Inc | 1,234 | 12.3% |
| 137 | Medinotec Inc | 59 | - |
| 138 | Alpha Pro Tech Ltd | 1,234 | 12.3% |
| 139 | Positron Corporation | 1,234 | 12.3% |
| 140 | Myomo Inc | 1,234 | 12.3% |
| 141 | Vaso Corporation | 1,234 | 12.3% |
| 142 | Rosecliff Acquisition Corp I | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Medinotec Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-10-20. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Medinotec Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Equipment & Supplies industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (331 companies). See the full Medical Equipment & Supplies industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 49.64 % | 49.59 % (avg) | +0.1 pp |
| Operating Margin | 6.58 % | industry median | +8.9 pp |
| EBITDA Margin | 7.31 % | -6.62 % (avg) | +13.9 pp |
| Capital Intensity (Capex / Revenue) | - | 7.55 % (avg) | - |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Medinotec Inc's Valuation vs Competitive Position
Valuation multiples vs the Medical Equipment & Supplies industry average (331 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Medical Equipment & Supplies industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 35.6x | - |
| EV / EBITDA | 75.5x | 17.7x | +57.8x |
| P/B | 10.8x | 4.5x | +6.3x |
| Return on Equity | 10.97 % | industry aggregate | 29.12 % |
| Return on Invested Capital | 5.25 % | -3.24 % (avg) | 8.49 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Medinotec Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue Growth | - | 158.20 % | 45.23 % |
| Operating Margin | 10.20 % | 18.78 % | 29.02 % |
| Return on Invested Capital | 6.34 % | 29.80 % | 31.04 % |
| P/E | - | 71.4x | 25.0x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Medinotec Inc's Strategic Group Map
Every company in Medinotec Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Medinotec Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Medinotec Inc's BCG Growth-Share Matrix
Relative market share (vs Medinotec Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Medinotec Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 9.2% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Medinotec Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 606 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Medinotec Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Medinotec Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Medinotec Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Medinotec Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Medinotec Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 8.9 points above the industry median.
- Return on equity 29.1 points above the industry aggregate.
- Latest-quarter revenue run-rate is accelerating (+25.4% annualized vs trailing 12 months).
Weaknesses
- Low relative market share vs the industry leader (0.00x).
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Medinotec Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Medinotec Inc | 2.26 | 5.51 | 0.04 |
| Intuitive Surgical Inc | 1.43 | 4.80 | - |
| Medtronic Plc | 0.15 | 2.10 | 0.57 |
| Stryker Corp | 0.48 | 1.99 | 0.68 |
| Boston Scientific Corporation | 0.25 | 1.54 | 0.47 |
| Edwards Lifesciences Corporation | 1.74 | 4.14 | 0.06 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Medinotec Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Medinotec Inc | Q3 2026 | -1.1 % | -88.2 % |
| Intuitive Surgical Inc | Q2 2026 | +29.3 % | +23.9 % |
| Medtronic Plc | Q2 2026 | +13.7 % | +41.3 % |
| Stryker Corp | Q2 2026 | +9.4 % | +44.3 % |
| Boston Scientific Corporation | Q2 2026 | +7.5 % | +13.8 % |
| Edwards Lifesciences Corporation | Q2 2026 | +13.7 % | -27.2 % |
| PEERS TOTAL | +9.8 % | +45.6 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Medinotec Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Medinotec Inc | Q3 2026 | +32.9 % | - |
| Intuitive Surgical Inc | Q2 2026 | +13.4 % | -27.5 % |
| Medtronic Plc | Q2 2026 | +13.8 % | -0.2 % |
| Stryker Corp | Q2 2026 | -4.1 % | +10.4 % |
| Boston Scientific Corporation | Q2 2026 | -2.6 % | +24.2 % |
| Edwards Lifesciences Corporation | Q2 2026 | +14.1 % | +35.7 % |
Medinotec Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Medinotec Inc | 8.67% | 8.12% | 10.97% |
| Intuitive Surgical Inc | 15.63% | 17.11% | 17.82% |
| Medtronic Plc | 5.71% | 6.46% | 10.64% |
| Stryker Corp | 7.89% | 8.80% | 16.36% |
| Boston Scientific Corporation | 8.34% | 9.91% | 14.77% |
| Edwards Lifesciences Corporation | 7.41% | 8.39% | 9.65% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Medinotec Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Medinotec Inc | 66.82 | 5.76 |
| Intuitive Surgical Inc | 48.83 | 13.45 |
| Medtronic Plc | 279.79 | 3.26 |
| Stryker Corp | 31.34 | 4.52 |
| Boston Scientific Corporation | 18.39 | 3.19 |
| Edwards Lifesciences Corporation | 51.25 | 7.90 |
| PEERS AVERAGE | 34.92 | 4.34 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.